Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Investors Should Brace for a Busy Week From the Biotech Sector

Page 1 of 2

With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with three separate events from the Food and Drug Administration likely to garner a lot of attention.

Anoro ellipta
On Tuesday, Theravance Inc (NASDAQ:THRX) and GlaxoSmithKline plc (ADR) (NYSE:GSK) are scheduled to meet with the FDA panel with regard to their chronic obstructive pulmonary disease inhaler anoro ellipta. If the briefing documents released Friday are any indication of how the meeting will go, shareholders in both companies should be fairly excited with the FDA finding only benign problems with the drug and noting it was quite effective in both doses.

Theravance Inc (NASDAQ:THRX)

If recommended positively by the FDA’s panel and approved by its PDUFA date in mid-December, anoro ellipta would become the second long-acting COPD inhaler developed by the collaboration of Theravance Inc (NASDAQ:THRX) and GlaxoSmithKline plc (ADR) (NYSE:GSK) to make it to market in less than a year — the other being Breo Ellipta. It would also firmly solidify GlaxoSmithKline plc (ADR) (NYSE:GSK) and Theravance Inc (NASDAQ:THRX) as the premier COPD drugmakers.

However, there are other beneficiaries here, too. Elan Corporation, plc (ADR) (NYSE:ELN), which is in the process of being purchased by Perrigo for $8.6 billion, took a $1 billion stake in Theravance Inc (NASDAQ:THRX) back in May for 21% of the royalties earned by Theravance Inc (NASDAQ:THRX) from the sale of its four-drug COPD partnership with GlaxoSmithKline plc (ADR) (NYSE:GSK). Should anoro ellipta be viewed favorably this week and eventually approved, it becomes a positive for Elan Corporation, plc (ADR) (NYSE:ELN) which promised to return some of those royalties to shareholders as a dividend and thus Perrigo as well.

On Thursday, Roche Holding Ltd. (ADR) (OTCBB:RHHBY) shareholders can look forward to an FDA panel meeting of their own. Already approved to treat metastatic HER2-positive breast cancer in combination with Herceptin and docetaxel for patients that haven’t received any prior chemotherapy, Roche Holding Ltd. (ADR) (OTCBB:RHHBY) is hoping to add an additional indication (known as a supplemental biologics license application, or sBLA) for Perjeta to be used as a neoadjuvant treatment (i.e., before surgery) in for patients with early stage HER2-positive breast cancer.

In the company’s Neosphere study which involved 417 people who had recently been diagnosed with early stage HER2-positive breast cancer, the combination of Perjeta, Herceptin, and docetaxel induced a pathological complete response (pCR) in 45.8% of patients which was 58% higher than the next closest therapy option of the combination of Herceptin and docetaxel which delivered a pCR of 29%. In its Tryphaena study, the combination of drugs proved favorable in turning in no more serious adverse events than the current standard of treatment.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!